Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.
Smith
Matthew R
MR
Massachusetts General Hospital Cancer Center, Yawkey Center 7038, 55 Fruit Street, Boston, MA 02114, USA. smith.matthew@mgh.harvard.edu